Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral CAN1012 in Advanced Solid Tumors
NCT04987112Phase 1Recruiting
- Sponsor
- Canwell Biotech Ltd.
- Start
- Jan 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAN1012 in solid tumor (advanced stage), sponsored by Canwell Biotech Ltd. Primary endpoints: Safety and Tolerability at 12 months, Recommended Phase 2 Dose at 12 months and 1 more. Started Jan 2022; status: recruiting.
02
Drugs
CAN1012
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04987112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04987112.